Non-Hodgkin's LymphomaPhase 3NCT01332968
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
A Phase 3 study testing Obinutuzumab, Cyclophosphamide and Doxorubicin in people with Non-Hodgkin's Lymphoma, run by Hoffmann-La Roche at 183 sites in 18 countries.
Trial summary
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Hodgkin's Lymphoma
- What is being tested?
- Obinutuzumab, Cyclophosphamide and Doxorubicin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,401 participants
- Where
- 183 sitesin 18 countries
- Study dates
- 6 Jul 2011to 30 Jul 2021
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Cluster of differentiation 20 (CD20)-positive indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma or splenic, nodal or extranodal marginal zone lymphoma)
- Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])
- For participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria
- For participants with symptomatic splenic, nodal, or non-gastric extranodal marginal zone lymphoma: disease that is de novo or has relapsed following local therapy (i.e. surgery or radiotherapy) and requires therapy as assessed by the investigator
- At least one bi-dimensionally measurable lesion (greater than [>] 2 cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Adequate hematologic function
Who cannot join
- Central nervous system lymphoma, leptomeningeal lymphoma, or histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenström's macroglobulinaemia
- Ann Arbor Stage I disease
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
- For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy
Show all 19Show fewer
- For participants with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy
- Regular treatment with corticosteroids during the 4 weeks prior to the start of Cycle 1
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- For participants who will be receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP): left ventricular ejection fraction (LVEF) less than (<) 50% by multiple-gated acquisition (MUGA) scan or echocardiogram
- History of prior other malignancy with the exception of curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study
- Known active infection, or major episode of infection within 4 week prior to the start of Cycle 1
- Vaccination with a live vaccine within 28 days prior to randomization
- Recent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosis
- Abnormal laboratory values as defined by protocol for creatinine, creatinine clearance, aspartate transaminase (AST) or alanine transaminase (ALT), total bilirubin, international normalized ration (INR), partial thromboplastin time (PTT) or activated partial thromboplastin time (aPPT), unless these abnormalities are due to underlying lymphoma
- Positive test results for human immunodeficiency virus (HIV), human T-lymphotropic virus 1 (HTLV1), hepatitis C or chronic hepatitis B
- Pregnant or lactating women
- Life expectancy <12 months
- Participation in another clinical trial with drug intervention within 28 days prior to start of Cycle 1 and during study
Trial locations and contacts
183 sites in 18 countries.
183 sites in 18 countries
Germany45 sites
Onkologischer Schwerpunkt am Oskar-Helene-Heim; Dres. Herrenberger, Keitel-Wittig u. Kirsch
Berlin, 14195
Klinikum Chemnitz gGmbH Krankenhaus Küchwald Klinik f.Innere Medizin III
Chemnitz, 09113
Klinik der Uni zu Köln; Klinik für Innere Medizin
Cologne, 50924
Städtisches Klinikum Dessau
Dessau, 06847
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
Dresden, 01307
Gemeinschaftspraxis Dr. med. J. Mohm und Dr. med. G. Prange-Krex; Fachaerzte fuer Innere Medizin
Dresden, 01307
HELIOS Klinikum Erfurt I.Medizinische Klinik
Erfurt, 99089
St.-Antonius-Hospital gGmbH; Klinik für Hämatologie und Onkologie
Eschweiler, 52249
Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
Essen, 45122
Klinik Johann Wolfgang von Goethe Uni; Medizinische Klinik II
Frankfurt, 60596
Universitätsklinikum Freiburg; Klinik für Innere Medizin I; Hämatologie/Onkologie
Freiburg im Breisgau, 79106
Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie
Göttingen, 37075
Universitätsklinikum Greifswald Klinik für Innere Medizin C und Poliklinik
Greifswald, 17475
Kath. Krankenhaus Hagen gem. GmbH, St.-Josefs-Hospital; Klinik für Hämatologie und Onkologie
Hagen, 58097
Onkologische Schwerpunktpraxis Dres. Bernd Gaede, Hans-Ulrich Ehlers, Ulrike Rodewig u.w.
Hanover, 30171
Dres.Andreas Karcher und Stefan Fuxius
Heidelberg, 69115
Uniklinik Heidelberg, Medizinische Klinik & Poliklinik V
Heidelberg, 69120
Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I
Homburg/Saar, 64421
Universitätsklinikum Jena; Klinik für Innere Medizin II
Jena, 07747
UKSH, Campus Kiel; Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie
Kiel, 24105
Institut für Versorgungsforschung in der Onkologie GbR Koblenz
Koblenz, 56068
Tagesklinik Landshut; Hämatologie/Onkologie
Landshut, 84028
Gemeinschaftspraxis für Hämatologie und Onkologie
Lebach, 66822
Klinikum St.Georg gGmbH Klinik für Internistische Onkologie und Hämotologie
Leipzig, 04129
Klinikum der Stadt Ludwigshafen; Medizinische Klinik A
Ludwigshafen, 67063
Onkologische Gemeinschaftspraxis
Magdeburg, 39104
Otto von Guericke Uni Magdeburg Uniklinik; Hämatologie/Onkologie
Magdeburg, 39120
Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik
Mainz, 55131
Mannheimer Onkologie Praxis Dres. Jürgen Brust Dieter Schuster
Mannheim, 68161
Klinikum Mannheim III. Medizinische Klinik
Mannheim, 68167
St. Frankziskus Krankenhaus, Med. Klinik I; Klinik für Hämatologie,Onkologie u. Gastroenterologie
Mönchengladbach, 41063
Klinikum der Universität München, Campus Großhadern; Medizinische Klinik und Poliklinik III
München, 81377
Klinikum rechts der Isar der TU München; III. Medizinischen Klinik (Hämatologie/Onkologie)
München, 81675
Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin
Mutlangen, 73557
Gemeinschaftspraxis Dr. med. Holger Klaproth
Neunkirchen/Saar, 66538
Pius-Hospital; Klinik fuer Haematologie und Onkologie
Oldenburg, 26121
Brüderkrankenhaus St. Josef
Paderborn, 33098
Prosper-Hospital, Medizinische Klinik I
Recklinghausen, 45659
Krankenhaus Barmherziger Brüder; Klinik für Internistische Onkologie / Hämatologie
Regensburg, 93049
Praxis für Hämatologie & Onkologie
Saarbrücken, 66113
Krankenhaus der Barmherzigen Brüder Trier; Innere Medizin I, Hämatologie / Internistische Onkologie
Trier, 54292
Universität Tübingen; Med. Klinik; Innere Medizin I
Tübingen, 72076
Universtitätsklinikum Ulm; Klinik für Innere Medizin III
Ulm, 89081
Helios Dr. Horst Schmidt Kliniken; Klinik Innere MED III: Hämatologie, Onkologie, Palliativmedizin
Wiesbaden, 65199
Hämatologisch-Onkologische Schwerpunktpraxis Dres. Schlag & Schöttker
Würzburg, 97080
United Kingdom29 sites
Aberdeen Royal Infirmary; Haematology - Ward 16
Aberdeen, AB25 2ZN
Queen Elizabeth Hospital; Centre for Clinical Haematology
Birmingham, B15 2TH
Royal Bournemouth General Hospital; Haematology
Bournemouth, BH7 7DW
Bristol Haematology and Oncology Centre
Bristol, BS2 8ED
Addenbrookes Hospital; Haematology
Cambridge, CB2 0QQ
Kent & Canterbury Hospital; Clinical Haematology
Canterbury, CT1 3NG
Velindre NHS Trust; Haematology Department
Cardiff, CF14 2TL
Castle Hill Hospital; The Queens Centre for Oncology and Haematology
Cottingham, HU16 5JG
Western General Hospital; Department of Haematology
Edinburgh, EH4 2XU
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN
James Paget Hospital; Haematology Department
Great Yarmouth, NR31 6LA
Princess Alexandra Hospital; Department of Haematology
Harlow, CM20 1QX
St James Uni Hospital; Icrf Cancer Medicine Research Unit
Leeds, LS9 7TF
Leicester Royal Infirmary; Dept of Haematology
Leicester, LE1 5WW
St Bartholomew's Hospital
London, EC1M 6BQ
King'S College Hospital; Haematology
London, SE5 9RS
St. George'S Hospital; Haematology
London, SW17 0QT
Hammersmith Hospital; Haematology
London, W12 OHS
University College Hospital; Macmillan Cancer Centre
London, WC1E 6AG
Christie Hospital; Breast Cancer Research Office
Manchester, M20 4QL
Norfolk & Norwich Hospital; Dept of Haematology
Norwich, NR4 7UY
Nottingham City Hospital; Dept of Haematology
Nottingham, NG5 1PB
Churchill Hospital; Oxford Cancer and Haematology Centre
Oxford, OX3 7LJ
Queen Alexandra Hospital; Haematology and Oncology Centre
Portsmouth, PO6 3LY
Southampton General Hospital; Medical Oncology
Southampton, SO16 6YD
Royal Marsden Hospital; Dept of Medical Oncology
Sutton, SM2 5PT
Singleton Hospital; Pharmacy
Swansea, SA2 8QA
Great Western;Department of Haematology
Swindon, SN3 6BB
Royal Cornwall Hospital; Haematology Clinic
Truro, TR1 3LJ
Japan24 sites
Aichi Cancer Center Hospital; Hematology and Cell Therapy
Aichi, 464-8681
Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital; Hematology & Oncology
Aichi, 466-8650
Nagoya City University Hospital; Hematology and Oncology
Aichi, 467-8602
Aomori Prefectural Central Hospital; Hematology
Aomori, 030-8553
Chiba Cancer Center;Hematology and Oncology
Chiba, 260-8717
National Cancer Center Hospital East;Hematology
Chiba, 277-8577
Shikoku Cancer Center; Hematology and Oncology
Ehime, 791-0280
National Hospital Organization Kyushu Cancer Center; Hematology
Fukuoka, 811-1395
Gunma University Hospital;Hematology
Gunma, 371-8511
Hiroshima University Hospital; Hematology
Hiroshima, 734-8551
Kobe City Medical Center General Hospital; Hematology
Hyōgo, 650-0047
Hyogo Cancer Center; Department of hematology
Hyōgo, 673-8558
Tokai University Hospital; Hematology
Kanagawa, 259-1193
Kumamoto University Hospital; Hematology Rheumatology and Clinical Immunology
Kumamoto, 860-8556
University Hospital, Kyoto Prefectural University of Medicine; Hematology
Kyoto, 602-8566
Tohoku University Hospital; Hematology and Immunology
Miyagi, 980-8574
Shinshu University Hospital; Hematology
Nagano, 390-8621
Niigata Cancer Center Hospital; Internal Medicine
Niigata, 951-8566
Matsushita Memorial Hospital; hematology
Osaka, 570-8540
Jichi Medical University Hospital; Hematology
Tochigi, 329-0498
National Cancer Center Hospital; Hematology
Tokyo, 104-0045
Toranomon Hospital; Hematology
Tokyo, 105-8470
The Cancer Institute Hospital of JFCR; Hematology Oncology
Tokyo, 135-8550
The Jikei University Daisan Hospital; Department of Clinical Oncology and Hematology
Tokyo, 201-8601
China13 sites
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, 100021
Peking University First Hospital
Beijing, 100034
Beijing Cancer Hospital
Beijing, 100142
General Hospital of Chinese PLA; Department of Hematology
Beijing, 100853
the First Hospital of Jilin University
Changchun, 130021
Fujian Medical University Union Hospital
Fuzhou, 350001
Sun Yet-sen University Cancer Center
Guangzhou, 510060
Harbin Medical University Cancer Hospital
Harbin, 150081
Jiangsu Province Hospital
Nanjing, 210036
Jiangsu Cancer Hospital
Nanjing, 211100
Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
Shanghai, 200025
Fudan University Shanghai Cancer Center
Shanghai, 200120
Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
Wuhan, 430023
United States12 sites
San Juan Oncology Associates
Farmington, New Mexico, 87401
Illinois Cancer Care, P.C. - Galesburg
Galesburg, Illinois, 61401
The Regents of the University of California; Office of Research
Irvine, California, 92697
MT Cancer Inst Fndtn; MT Can Spec
Missoula, Montana, 59802
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Kootenai Cancer Center
Post Falls, Idaho, 83854
Siouxland Hematology/Oncology
Sioux City, Iowa, 51101
Highlands Oncology Group
Springdale, Arkansas, 72762
Mercy Medical Research Institute
Springfield, Missouri, 65807
Northwest Medical Specialties
Tacoma, Washington, 98405
University of Kansas; Medical Center & Medical pavilion
Westwood, Kansas, 66205
Cancer Center of Kansas
Wichita, Kansas, 67214-3728
Italy9 sites
ASST PAPA GIOVANNI XXIII; Ematologia
Bergamo, Lombardy, 24127
Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
Milan, Lombardy, 20122
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
Milan, Lombardy, 20162
Azienda Ospedaliera Universitaria di Modena
Modena, Emilia-Romagna, 41100
Uni Degli Studi; Dip.Med.Clinica E Sperim. Ematologia
Padova, Veneto, 35128
Ospedale V. Cervello; U.O. Ematologia E Trapianti
Palermo, Sicily, 90146
Az. Osp. S. Camillo Forlanini; Uo Ematologia E Trapianti Di Midollo Osseo
Rome, Lazio, 00152
Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
Rozzano, Lombardy, 20089
A.O. Univ.Ospedali Riuniti Umerto I -G.M.Lancisi G.Salesi; U.O. Clinica Di Ematologia
Torrette DI Ancona, The Marches, 60020
Australia8 sites
St Vincent'S Hospital; Haematology
Fitzroy, Victoria, 3065
Peter MacCallum Cancer Centre; Department of Haematology
Melbourne, Victoria, 3002
Austin and Repatriation Medical Centre; Cancer Services
Melbourne, Victoria, 3084
Monash Medical Centre; Haematology
Melbourne, Victoria, 3168
Fiona Stanley Hospital
Murdoch, Western Australia, 6150
Concord Repatriation General Hospital; Haematology
Sydney, New South Wales, 2139
Westmead Hospital; Haematology
Sydney, New South Wales, 2145
Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
Woolloongabba, Queensland, 4102
Canada8 sites
Tom Baker Cancer Centre-Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Hopital Charles Lemoyne; Centre Integre de Lutte Contre Le Cancer de La Monteregie
Greenfield Park, Quebec, J4V 2H1
Dr. Georges L. Dumont University Hospital Centre
Moncton, New Brunswick, E1C 8X3
Ottawa General Hospital
Ottawa, Ontario, K1H 8L6
North York General Hospital
Toronto, Ontario, M2K 1E1
Humber River Hospital
Toronto, Ontario, M3M 0B2
Toronto East General Hospital; Haematology/Oncology
Toronto, Ontario, M4C 3E7
France7 sites
Hotel Dieu; Medecine D
Angers, 49933
Hopital Augustin Morvan; Hematologie
Brest, 29609
Chu Estaing; Hematologie Clinique Adultes
Clermont-Ferrand, 63003
Clinique Victor Hugo
LeMans, 72000
Hopital De La Conception; Hematologie Clinique
Marseille, 13005
Hopital Saint Eloi; Hematologie Oncologie Medicale
Montpellier, 34295
Hopital Saint Jean; Hematologie
Perpignan, 66046
Spain6 sites
Fundacion Hospital de Alcorcon; Servicio de Hematologia
Alcorcón, Madrid, 28922
Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
Badalona, Barcelona, 08915
Hospital de Basurto; Servicio de Hematologia
Bilbao, Vizcaya, 48013
Hospital Univ. 12 de Octubre; Servicio de Hematologia
Madrid, 28041
Hospital Universitario la Paz; Servicio de Hematologia
Madrid, 28046
Corporacio Sanitaria Parc Tauli; Servicio de Hematologia
Sabadell, Barcelona, 08208
Hungary5 sites
Semmelweis University, First Dept of Medicine
Budapest, 1083
National Institute of Oncology, A Dept of Internal Medicine
Budapest, 1122
University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology
Debrecen, 4032
Petz Aladar Megyei Korhaz; Hematologia
Győr, 9024
University of Szeged, II Dept of Internal Medicine
Szeged, 6720
Belgium3 sites
UZ Gent
Ghent, 9000
AZ Groeninge
Kortrijk, 8500
UZ Leuven Gasthuisberg
Leuven, 3000
Czechia3 sites
Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
Brno, 625 00
Fn Hr. Kralove; IV. Interni Hematologicka Klinika
Hradec Králové, 500 05
Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
Prague, 128 08
Israel3 sites
Rambam Medical Center; Heamatology & Bone Marrow Transplantation
Haifa, 3109601
Beilinson Medical Center; Haematology
Petah Tikva, 4910000
Chaim Sheba Medical Center; Hematology BMT & CBB
Ramat Gan, 5262100
Russia3 sites
FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF
Moscow, 115478
Regional Clinical Hospital N.A. Semashko; Hematology
Nizhny Novgorod, 603126
Republican Clinical Hospital n.a. Baranov; Haematology
Petrozavodsk, 185019
Taiwan3 sites
National Taiwan Universtiy Hospital; Division of Hematology
Taipei, 100
Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology
Taipei, 11259
Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology
Taoyuan, 333
Finland1 site
Helsinki University Central Hospital; Dept of Oncology
Helsinki, 00250
Sweden1 site
Sahlgrenska Universitetssjukhuset; Sektionen för hematologi och koagulation
Gothenburg, S-413 45
About this study
Official title: A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response [CR] or partial response [PR]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
- Conditions
- Non-Hodgkin's Lymphoma
- Being tested
- Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Medical subject headings
- Lymphoma, Non-Hodgkin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObinutuzumabDrug
Also called GA101; RO5072759
Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
CyclophosphamideDrug
Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
DoxorubicinDrug
Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
VincristineDrug
Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
PrednisoneDrug
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
BendamustineDrug
Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
RituximabDrug
Also called MabThera/Rituxan
Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
| Study group | Role | What they receive |
|---|---|---|
| Rituximab+Chemotherapy | Active comparator | Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study. Receives: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Bendamustine; Drug: Rituximab |
| Obinutuzumab+Chemotherapy | Experimental | Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study. Receives: Drug: Obinutuzumab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone; Drug: Bendamustine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Measured: Baseline up to data cut-off (up to approximately 4 years and 7 months)
Secondary outcomes (30)
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Measured: Baseline up to final analysis (up to 10 years)
Progression-Free Survival in the Overall Study Population, Investigator-Assessed
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
Progression-free survival in the participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI. In the first 170 patients with follicular lymphoma, an FDG-PET was mandatory where a PET scanner was available.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
Progression-free survival in the overall study population was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of IRC assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Overall Response (Follicular Lymphoma Population), Investigator-Assessed
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with and without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), Investigator-Assessed
Overall response in the overall study population was defined as percentage of participants with partial response (PR) or complete response (CR) determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without positron emission tomography (PET). CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), Investigator-Assessed
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), Investigator-Assessed
Percentage of participants with complete response in the overall study population was determined on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Follicular Lymphoma Population), IRC-Assessed
Overall response in the follicular lymphoma population was defined as percentage of participants with PR or complete response CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Overall Response (OR) = CR + PR.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), IRC-Assessed
Overall response in the overall study population was defined as percentage of participants with PR or CR determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions; PR was defined as >=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%; Overall Response (OR) = CR + PR.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), IRC-Assessed
Percentage of participants with complete response in the follicular lymphoma population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Measured: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), IRC-Assessed
Percentage of participants with complete response in the overall study population was determined on the basis of IRC assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI with or without PET. CR was defined as disappearance of all target lesions.
Measured: Baseline up to end of induction period (up to approximately 7 months)]
Overall Survival (Follicular Lymphoma Population)
Overall survival in the follicular lymphoma population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
Measured: Baseline up to 10 years
Overall Survival (Overall Study Population)
Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause. Reported is the percentage of participants with event.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Event-Free Survival (Follicular Lymphoma Population)
Event-free survival in the follicular lymphoma population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with an event.
Measured: Baseline up to 10 years
Event-Free Survival (Overall Study Population)
Event-free survival in the overall study population was defined as the time from the date of randomization to the date to disease progression/relapse, death from any cause, or initiation of a new anti-lymphoma treatment (NALT) on the basis of investigator assessment assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by CT/MRI. Reported is the percentage of participants with event.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Follicular Lymphoma Population)
Disease-free survival in the follicular lymphoma population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma (RRCML). Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Reported is the percentage of participants with event.
Measured: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Overall Study Population)
Disease-free survival in the overall study population was defined as the time from the date of the first occurrence of a documented CR to the date of disease progression/ relapse, or death from any cause for the subgroup of participants with a response of CR at any time prior to NALT on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Reported is the percentage of participants with event.
Measured: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm.
Measured: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
DOR was defined as the time from first occurrence of a documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR any time prior to NALT based on RRCML. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. PR was defined as >/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodules must have regressed by >/= 50%. Progression/relapse was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm.
Measured: From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)
Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
Measured: Baseline up to 10 years
Time to Next Anti-Lymphoma Treatment (Overall Study Population)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause. Reported is the percentage of participants with event.
Measured: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Measured: Baseline up to 10 years
Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
FACT-G consists of the following 4 FACT-Lym sub-questionnaires: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24) and Functional Well-being (range: 0-28). Higher scores indicate better outcomes. A positive change from baseline indicates improvement. Maint = Maintenance period.
Measured: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
The FACT-Lym TOI Score for the follicular lymphoma population was derived from the following 3 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym TOI Score is the sum of the 3 individual subscales (range 0-116). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Measured: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
The FACT-Lym Individual Subscale Lymphoma Score for the follicular lymphoma population was derived from the Lymphoma subscale questionnaire (range: 0-60). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Measured: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
The FACT-Lym Total Score for the follicular lymphoma population was derived from the following 5 individual FACT-Lym questionnaire subscale scores: Physical Well-being (range: 0-28), Social/Family Well-being (range: 0-28), Emotional Well-being (range: 0-24),Functional Well-being (range: 0-28) and Lymphoma (range: 0-60). The FACT-Lym Total Score is the sum of all 5 individual subscales (range 0-168). Higher scores indicate better outcomes. A positive change from baseline indicates an improvement.
Measured: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Completion (Compl) includes completion visit and early termination visit. Maintenance/Observation is indicated as Maint/Obs.
Measured: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1 Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs. Completion includes completion visit and early termination visit.
Measured: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
The EQ-5D is a quality of life questionnaire with five questions, each with three categories (no problem, moderate problem, severe problems) and a visual analogue scale (VAS) from 0 (worst possible health state) to 100 (best possible health state. Summary score ranges from 0 to 1. Higher scores indicate better outcomes. A positive change from baseline indicates an improvement. Maintenance/Observation is indicated as Maint/Obs in data categories. Completion includes completion visit and early termination visit.
Measured: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2011 (estimated)
- Study start6 Jul 2011
- Primary completion1 Feb 2016
- Study completion30 Jul 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for Non-Hodgkin's LymphomaStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,401 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- German Low Grade Lymphoma Study Group, Institute of Cancer Research, United Kingdom
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01332968
- Sponsor's protocol ID
- BO21223
- Other IDs
- 2010-024132-41
- Status last verified
- Aug 2022
- First submitted
- 8 Apr 2011
- Last updated
- 11 Aug 2022
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Jorgensen JB, Hansen KV, Nielsen LK, Gade IL, Pedersen MA, Jensen P, Simonsen MR, Knapp A, Gormsen LC, El-Galaly TC. First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM study. Leuk Lymphoma. 2026 May;67(6):1352-1361. doi: 10.1080/10428194.2026.2642931. Epub 2026 Mar 25.
PubMed 41879719Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, Jagt RV, Janssens A, Kneba M, Mayer J, Young M, Schmidt C, Knapp A, Nielsen T, Brown H, Spielewoy N, Harbron C, Bottos A, Mundt K, Marcus R, Hiddemann W, Hoster E. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. J Clin Oncol. 2024 Feb 10;42(5):550-561. doi: 10.1200/JCO.23.00838. Epub 2023 Dec 14.
PubMed 38096461Pedersen MA, Gormsen LC, Jakobsen LH, Eyre TA, Severinsen MT, Baech J, Dann EJ, Knapp A, Sahin D, Vestergaard P, El-Galaly TC, Jensen P. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. Br J Haematol. 2024 Apr;204(4):1271-1278. doi: 10.1111/bjh.19194. Epub 2023 Nov 13.
PubMed 37957542Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus RE, Seymour JF, Launonen A, Knapp A, Nielsen TG, Mir F. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):40-48. doi: 10.1016/j.clml.2022.09.003. Epub 2022 Oct 4.
PubMed 36379880Hong X, Song Y, Shi Y, Zhang Q, Guo W, Wu G, Li J, Feng J, Kinkolykh A, Knapp A, Lin T. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. Chin Med J (Engl). 2021 Sep 16;135(4):433-440. doi: 10.1097/CM9.0000000000001737.
PubMed 35194005Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.
PubMed 34323957Davies A, Trask P, Demeter J, Florschutz A, Hanel M, Kinoshita T, Pettengell R, Quach H, Robinson S, Sadullah S, Sancho JM, Udvardy M, Witzens-Harig M, Knapp A, Liu W. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020 Dec;99(12):2837-2846. doi: 10.1007/s00277-020-04021-6. Epub 2020 Apr 20.
PubMed 32314038Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.
PubMed 31053601Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
PubMed 30341058Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptacnik V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8.
PubMed 30309758Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
PubMed 29856692Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
PubMed 28976863
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders
- ClinicalTrials.gov ID
- NCT01332968
- Acronym / sponsor ID
- BO21223
- Conditions
- Non-Hodgkin's Lymphoma
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,401 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Collaborators
- German Low Grade Lymphoma Study Group, Institute of Cancer Research, United Kingdom
- Study start
- 6 Jul 2011 (actual)
- Primary completion
- 1 Feb 2016 (actual)
- Study completion
- 30 Jul 2021 (actual)
- First posted
- 11 Apr 2011 (estimated)
- Results
- Posted 7 Jun 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab maintenance in participants with untreated advanced indolent non-Hodgkin's lymphoma. After the end of the induction period, participants achieving response (Complete response [CR] or partial response [PR]) will undergo a maintenance period continuing on the randomized antibody treatment alone every 2 months until disease progression for a total of 2 years. Anticipated time on study treatment is up to approximately 2.5 years. After maintenance or observation, participants will be followed for 5 years until progression. After progression, participants will be followed for new anti-lymphoma therapy and overall survival until the end of the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rituximab+Chemotherapy | Active comparator | Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Vincristine, Drug: Prednisone, Drug: Bendamustine, Drug: RituximabParticipants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study. |
| Obinutuzumab+Chemotherapy | Experimental | Drug: Obinutuzumab, Drug: Cyclophosphamide, Drug: Doxorubicin, Drug: Vincristine, Drug: Prednisone, Drug: BendamustineParticipants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Cluster of differentiation 20 (CD20)-positive indolent B-cell non-Hodgkin's lymphoma (follicular lymphoma or splenic, nodal or extranodal marginal zone lymphoma)
- Stage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])
- For participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria
- For participants with symptomatic splenic, nodal, or non-gastric extranodal marginal zone lymphoma: disease that is de novo or has relapsed following local therapy (i.e. surgery or radiotherapy) and requires therapy as assessed by the investigator
- At least one bi-dimensionally measurable lesion (greater than [>] 2 cm in its largest dimension by computed tomography [CT] scan or magnetic resonance imaging [MRI])
Key exclusion criteria (19 listed)
- Central nervous system lymphoma, leptomeningeal lymphoma, or histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
- Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenström's macroglobulinaemia
- Ann Arbor Stage I disease
- History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
- Known hypersensitivity to any of the study drugs or sensitivity to murine products, or history of sensitivity to mannitol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObinutuzumabAlso: GA101; RO5072759Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period. | Drug | Obinutuzumab+Chemotherapy |
| CyclophosphamideCyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| DoxorubicinDoxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| VincristineVincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| PrednisonePrednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| BendamustineBendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period. | Drug | Obinutuzumab+Chemotherapy, Rituximab+Chemotherapy |
| RituximabAlso: MabThera/RituxanRituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period. | Drug | Rituximab+Chemotherapy |
Primary outcome
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Time frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)
Progression-free survival in participants with follicular lymphoma was defined as the time from randomization until the first documented day of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments according to the Revised Response Criteria for Malignant Lymphoma. Progression was defined as at least 50% increase in nodal lesions or >/=50% increase in any node > 1 centimeter (cm) or >/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion > 1.5 cm or >/= 50% increase in any previously involved node with a diameter </= 1 cm such that it is now >1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
30 secondary outcomes
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed
Time frame: Baseline up to final analysis (up to 10 years)
Progression-Free Survival in the Overall Study Population, Investigator-Assessed
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Follicular Lymphoma Population), IRC-Assessed
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Progression-Free Survival (Overall Study Population), Assessed by Independent Review Committee (IRC)
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Overall Response (Follicular Lymphoma Population), Investigator-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), Investigator-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), Investigator-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), Investigator-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Follicular Lymphoma Population), IRC-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Overall Response (Overall Study Population), IRC-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Follicular Lymphoma Population), IRC-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)
Complete Response (Overall Study Population), IRC-Assessed
Time frame: Baseline up to end of induction period (up to approximately 7 months)]
Overall Survival (Follicular Lymphoma Population)
Time frame: Baseline up to 10 years
Overall Survival (Overall Study Population)
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Event-Free Survival (Follicular Lymphoma Population)
Time frame: Baseline up to 10 years
Event-Free Survival (Overall Study Population)
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Follicular Lymphoma Population)
Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Disease-Free Survival (Overall Study Population)
Time frame: From first occurrence of documented CR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Follicular Lymphoma Population), Investigator-Assessed
Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 5 years and 2 months)
Duration of Response (DOR) (Overall Study Population), Investigator-Assessed
Time frame: From first occurrence of documented CR or PR to data cut-off (up to approximately 4 years and 7 months)
Time to Next Anti-Lymphoma Treatment (Follicular Lymphoma Population)
Time frame: Baseline up to 10 years
Time to Next Anti-Lymphoma Treatment (Overall Study Population)
Time frame: Baseline up to data cut-off (up to approximately 5 years and 2 months)
Percentage of Participants With Adverse Events
Time frame: Baseline up to 10 years
Change From Baseline in All Domains of FACT-G (Follicular Lymphoma Population)
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Total Outcome Index (TOI) Score (Follicular Lymphoma Population)
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in FACT-Lym Individual Subscale Lymphoma Score (Follicular Population)
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score (Follicular Population)
Time frame: Baseline (Induction Cycle 1, Day 1), data cut-off (up to approximately 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Induction Phase
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Maintenance/Observation Phase
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 months after Day 1 of last induction cycle, Follow-up: every year up to data cut-off (up to 5 years and 2 months)
Change From Baseline in Euro-Quality of Life-5 Dimensions (EQ-5D) Questionnaire Summary Score (Follicular Lymphoma Population) During Follow Up Phase
Time frame: Induction: Cycle 1 Day 1 (Baseline), Cycle 3 Day 1, End of Induction (up to 7 months); Maintenance: 2, 12 after Day 1 of last induction cycle, Follow-up: every year for up to data cut-off (up to 5 years and 2 months)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2022.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41879719Jorgensen JB, Hansen KV, Nielsen LK, Gade IL, Pedersen MA, Jensen P, Simonsen MR, Knapp A, Gormsen LC, El-Galaly TC. First-line immunochemotherapy for indolent lymphoma does not affect muscle volume: a post hoc analysis of 472 patients in long-term remissions from the GALLIUM study. Leuk Lymphoma. 2026 May;67(6):1352-1361. doi: 10.1080/10428194.2026.2642931. Epub 2026 Mar 25.
- Derived from this study: PubMed 38096461Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, Jagt RV, Janssens A, Kneba M, Mayer J, Young M, Schmidt C, Knapp A, Nielsen T, Brown H, Spielewoy N, Harbron C, Bottos A, Mundt K, Marcus R, Hiddemann W, Hoster E. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study. J Clin Oncol. 2024 Feb 10;42(5):550-561. doi: 10.1200/JCO.23.00838. Epub 2023 Dec 14.
- Derived from this study: PubMed 37957542Pedersen MA, Gormsen LC, Jakobsen LH, Eyre TA, Severinsen MT, Baech J, Dann EJ, Knapp A, Sahin D, Vestergaard P, El-Galaly TC, Jensen P. The impact of CHOP versus bendamustine on bone mineral density in patients with indolent lymphoma enrolled in the GALLIUM study. Br J Haematol. 2024 Apr;204(4):1271-1278. doi: 10.1111/bjh.19194. Epub 2023 Nov 13.
- Derived from this study: PubMed 36379880Casulo C, Herold M, Hiddemann W, Iyengar S, Marcus RE, Seymour JF, Launonen A, Knapp A, Nielsen TG, Mir F. Risk Factors for and Outcomes of Follicular Lymphoma Histological Transformation at First Progression in the GALLIUM Study. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):40-48. doi: 10.1016/j.clml.2022.09.003. Epub 2022 Oct 4.
- Derived from this study: PubMed 35194005Hong X, Song Y, Shi Y, Zhang Q, Guo W, Wu G, Li J, Feng J, Kinkolykh A, Knapp A, Lin T. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study. Chin Med J (Engl). 2021 Sep 16;135(4):433-440. doi: 10.1097/CM9.0000000000001737.
- Derived from this study: PubMed 34323957Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985.
- Derived from this study: PubMed 32314038Davies A, Trask P, Demeter J, Florschutz A, Hanel M, Kinoshita T, Pettengell R, Quach H, Robinson S, Sadullah S, Sancho JM, Udvardy M, Witzens-Harig M, Knapp A, Liu W. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020 Dec;99(12):2837-2846. doi: 10.1007/s00277-020-04021-6. Epub 2020 Apr 20.
- Derived from this study: PubMed 31053601Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3.
- Derived from this study: PubMed 30341058Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19.
- Derived from this study: PubMed 30309758Trotman J, Barrington SF, Belada D, Meignan M, MacEwan R, Owen C, Ptacnik V, Rosta A, Fingerle-Rowson GR, Zhu J, Nielsen T, Sahin D, Hiddemann W, Marcus RE, Davies A; PET investigators from the GALLIUM study. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1530-1542. doi: 10.1016/S1470-2045(18)30618-1. Epub 2018 Oct 8.
- Derived from this study: PubMed 29856692Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Durig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
- Derived from this study: PubMed 28976863Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
Related trials for Non-Hodgkin's Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Not yet recruitingPhase 2
Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma
Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Active, not recruitingPhase 1
A Rollover Study of CC-122
Non-Hodgkin Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
183 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Obinutuzumab, Cyclophosphamide and Doxorubicin in people with Non-Hodgkin's Lymphoma, run by Hoffmann-La Roche at 183 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 183 sites in Germany, United Kingdom, Japan, China, United States and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Jun 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival in the Follicular Lymphoma Population, Investigator-Assessed (time frame: Baseline up to data cut-off (up to approximately 4 years and 7 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01332968, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2022.